Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 367

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 367
---
common stock obtained by dividing the liquidation preference thereof by $10.00 and the contingent right to receive such
holder’s Earn-Out Pro Rata Portion (as defined in the Business Combination Agreement), and (iv) each warrant to
purchase CERo preferred stock (each, a “CERo warrant”) outstanding as of immediately prior to the Effective Time will be
converted into a warrant to acquire a number of shares of Class A common stock equal to the number of shares of CERo preferred stock
subject to the corresponding warrant immediately prior to the Effective Time, multiplied by the Aggregate Liquidation
Preference of such underlying shares of CERo preferred stock, and divided by $10.00, with the exercise price per share
for such warrant equal to (A) the current aggregate exercise price of such warrant (the current exercise price per share of CERo
preferred stock applicable to the corresponding warrant immediately prior to the Effective Time, multiplied by the number
of shares of CERo preferred stock issuable upon exercise thereof), divided by (B) the number of shares of Class A
common stock issuable upon exercise thereof. Subject to certain exceptions, such terms and conditions applicable to a CERo Therapeutics
Holdings, Inc. (“New CERo”) warrant will be the same terms and conditions as were applicable to a CERo warrant immediately
prior to the Effective Time. The Company will issue an aggregate of approximately 5.0 million shares of Class A common stock
to the holders of CERo common stock and CERo preferred stock as consideration in the Business Combination.

NASDAQ Notice

On April 3, 2023, the Company received a letter
(the “Letter”) from the staff at The Nasdaq Global Market (“Nasdaq”) notifying the Company that, for the 30 consecutive
trading days prior to the date of the Letter, the Company’s common stock had traded at a value below the minimum $50,000,000 “Market
Value of Listed Securities” (“MVLS”) requirement set forth in Nasdaq Listing Rule 5450(b)(2)(A), which is required
for continued listing of the Company’s common stock on Nasdaq. The Letter is only a notification of deficiency, not of imminent
delisting, and has no current effect on the listing or trading of the Company’s securities on Nasdaq.

In order to bring the Company into compliance with
the MVLS requirement, on July 3, 2023, the